The effect of *Helicobacter pylori* eradication on proteinuria in patients with primary glomerulonephritis

Fatih Dede¹, Deniz Ayli¹, İpek Gonul², Osman Yuksel³, Ramazan Ozturk¹, Ayla Yildiz¹, Ezgi Yenigun¹, Serhan Piskinpasa¹, Didem Turgut¹, Eyup Koc¹, Ali Riza Odabas¹

Material and Methods: The study was composed of patients diagnosed with primary glomerulonephritis who had dyspeptic complaints throughout the diagnosis. Patients who received endoscopic biopsy upon the determination of pathologic findings in their upper gastrointestinal endoscopy were HP positive in their biopsy material. A triple eradication therapy was initiated for HP.

Results: The study included 14 female and 19 male patients, 33 in total, whose biopsy material was determined to be HP positive. Before the eradication for HP, we found serum albumin to be 34.0 (19.0–51.0) g/L, serum total protein 58.6 ±12.9 g/L, serum creatinine 0.9 (0.5–1.2) and proteinuria 3069 (652–12392) mg/day in 24-hour urine. After the eradication, however, serum albumin was found to be 40 (20–52) g/L, serum total protein 62.3 ±11.1 g/L, serum creatinine 1.02 (0.6–1.29) mg/dl and proteinuria was 2850 (172–15181) mg/day in 24-hour urine. A comparison of the results showed that a statistically significant difference is established between the serum albumin, total protein and creatinine values (p = 0.001, p = 0.001 and p = 0.021, respectively), but not between proteinuria values in 24-hour urine (p = 0.990).

Conclusions: Patients with primary glomerulonephritis, HP eradication treatment has an effect on serum albumin levels.

Key words: glomerulonephritis, *Helicobacter pylori*, proteinuria.
granular subepithelial deposits of IgG and C3. IgA nephropathy (IgAN) is defined as increased mesangial cellularity and mesangial deposition of IgA. Focal segmental glomerulosclerosis (FSGS) is characterized as segmental and/or focal sclerosis of glomeruli with or without hyalination and endocapillary hypercellularity. Mesangio proliferative glomerulonephritis (MzPGN) is described as increased mesangial cellularity and mesangial deposition of IgM and C3 without IgA. Membranoproliferative glomerulonephritis (MPGN) is defined as accumulation of extracellular material, a double contouring of the glomerular basal membrane, increased mesangial cellularity and IgM, IgG, and C3 in a glomerular capillary wall and mesangial areas [1–3]. Even though the pathogenesis of the disease includes various cytokines distorting glomerular basal membrane permeability and the resulting inflammatory process, cellular and humoral immune system activation and genetic factors, the immunologic mechanism of primary glomerulonephritis and the factors that trigger it have not been entirely enlightened [2].

*Helicobacter pylori* (HP) is a chronic infection closely related to numerous gastrointestinal diseases such as peptic ulcer, gastric adenoma and cancer [4, 5]. The reported prevalence of HP in the adult population is 67.6–81.3% in our country [6]. Although limited to the gastric mucosa, HP can trigger a local and systemic inflammatory response and consequently play a part in the development of various extragastrintestinal disorders [7–10]. The bacterial peptides of HP are considered to be effective in the pathogenesis of those diseases by chronically stimulating the immune system in various mechanisms. Gastric mucosa infected by HP stimulates the release of proinflammatory cytokines such as tumor necrosis factor α (TNF-α), interferon-γ (IFN-γ), interleukin-1 (IL-1), IL-6, IL-8, IL-10 and IL-12. It also triggers the cellular and humoral immune system and causes specific immune cell activation. Also it increases cytokines derived from mononuclear macrophages, stimulates neutrophil chemotaxis and its activation, and increases the expression and degranulation of adhesion molecules and the production of reactive oxygen metabolites. Therefore, it also stimulates specific immunity [4, 7, 11]. This local proinflammatory effect that HP has on gastric mucosa was thought to have a potential systemic effect and activate the immune response. Following the discovery of HP, its relation to pathologies such as thrombocytopenic purpura, coronary artery disease, respiratory disorders, iron deficiency, anemia and urticaria was studied [4, 7, 8, 10, 12].

In this study, we investigated the effect of HP eradication therapy on the remission of the disease in patients with primary glomerulonephritis and gastritis and peptic ulcer-like dyspeptic complaints who received upper gastrointestinal endoscopy resulting in the determination of pathology and HP diagnosis in their biopsy.

**Material and methods**

Of the 144 patients who applied to our hospital with proteinuria and were diagnosed with glomerulonephritis between December 2006 and January 2009, those with primary glomerulonephritis whose advanced tests excluded secondary reasons (systemic lupus erythematosus and other collagen vascular diseases, vasculitis, diabetes mellitus, amyloidosis, malignancies, drug-induced glomerulonephritis and concomitant glomerulonephritis to systemic diseases) were admitted to the study. Before the study, all the patients were informed about the process and treatment that would be applied throughout the study and their approval was received.

Of these 144 patients who were diagnosed with primary glomerulonephritis, 43 who had dyspeptic complaints at the time of diagnosis were prepared for upper gastrointestinal endoscopy. Thirty-nine patients who showed pathologic findings in endoscopy also received endoscopic biopsy, and HP was studied in the biopsy material. All patients who underwent biopsy received urea breath test simultaneously. A total of 33 patients whose biopsy material was found to be HP positive were studied and triple eradication therapy was started. The treatment involved omeprazole 40 mg/day, amoxicillin 2000 mg/day and clarithromycin 1000 mg/day for 14 days duration. Patients’ pre- and post-treatment biochemical parameters and proteinuria values were compared. The control of HP existence after triple eradication was made by urea breath test 3 weeks after the treatment. The process was repeated in 3 patients who were still positive in the urea breath test following eradication, and their biochemical data were obtained after negative urea breath test upon the consecutive treatment.

Blood samples were obtained from all participants via antecubital venipuncture by trained medical personnel in the fasting state. The blood and urine samples were analyzed on the same day without delay. A 24-hour urine was collected for the measurement of albumin and protein excretion rate in all subjects. Blood creatinine, protein, albumin, lipid parameters and urine creatinine and protein were analyzed with spectrophotometric methods; C-reactive protein (CRP) was analyzed with turbidimetric methods with a multichannel Synchron DxC 800 analyzer (Beckman Coulter, USA) [13]. Urea breath test was applied with 1µCi 14C-Urea capsules (Helicap, Heliprobe Breath Card, Kibion Ab, Uppsala, Sweden) [14]. Ultrasonography guided renal biopsies were performed with 16 gauge nee-
Findings before and after a S
glomerulonephritis

Characteristics of patients who displayed significant regression in proteinuria after
patients with renal lesion and/or hypertension at the time of diagnosis, those with a history of acid-
agents. The study protocol was approved by the local ethics committee.

774
F. Dede, D. Ayli, I. Gorul, O. Yuksel, A. Yildiz, E. Yenigun, S. Piskinpasa, D. Turgut, E. Koc, A.R. Odabas

Results
The study included 33 patients in total, 19 male and 14 female, whose biopsy material was deter-
tined to be HP positive. As the primary glomerulonephritis subgroup, we found IgAN in 10 (30.3%),
MGN in 7 (21.3%), MzPGN in 6 (18.2%), FSGS in 5 (15.1%), and MPGN in 5 (15.1%) patients. The
mean age of patients was 31.5 ±9.2 years. While patients’ hepatitis B and C virus antigen and anti-
body levels and serum autoantibody levels were all negative, their complement levels were within nor-
mal limits. HP was positive in 76.7% (33/43) of the patients who had dyspeptic complaints and pathol-
ogy. The most common endoscopic finding found in the patients was antral gastritis and pangastritis. While 15 (45.5%) had antral gastritis and 13 (39.4%) had pangastritis, 3 (9.1%) had bulbilis and 2 (6%) had erosive gastritis. The general character-
istics of patients before eradication and their laboratory data are given in Table I. In endoscopic biop-
sy materials, the histopathologic finding in all patients was coherent with chronic gastritis. Urea
breath test before eradication was positive in 29 of the 33 patients. After eradication, the urea breath
test of 3 patients was still positive. A second triple eradication therapy was administered in those
patients, after which control urea breath tests were found to be negative. Before the HP eradication
treatment, the serum albumin value was 34.0 (19.0–51.0) g/l, serum total protein was 58.6 ±12.9 g/l,
serum creatinine was 0.9 (0.5–1.2) mg/dl and proteinuria in 24-hour urine was 3069 (652–12392)
mg/day. After the eradication, however, serum albumin was 40 (20–52) g/l, serum total protein was
62.3 ±11.1 g/l, serum creatinine was 1.02 (0.6–1.29)
mg/dl and proteinuria in 24-hour urine was 2850
(172–15181) mg/day. When the results were com-
pared, there was a statistically significant differ-
ence between the values of serum albumin, total
protein and creatinine (p = 0.001, p = 0.001 and
p = 0.021, respectively), while there was not any
statistical difference between proteinuria values of
24-hour urine (p = 0.990) (Table II). Despite the sta-

tistically significant increase in serum creatinine
values, the serum creatinine values of all patients

Continuous variables are reported as mean (standard deviation) for normally distributed data or median (interquartile range) for asym-
metrically distributed data. Categorical variables are reported as num-
ber (percentage).

Endoscopic findings, n (%)

Table I Demographic features of patients

| Variable | All patients |
|----------|-------------|
| Number of patients, n (%) | 33 (100) |
| Male/female, n (%) | 19 (57)/14 (43) |
| Age [years] | 31.5 ±9.2 |
| Age (male/female) [years] | 32 ±8.9/30.8 ±9.7 |
| Subtype of glomerulonephritis, n (%) | |
| IgA nephropathy | 10 (30.3) |
| Membranous glomerulonephritis | 7 (21.3) |
| Membranoproliferative glomerulonephritis | 6 (18.2) |
| Focal segmental glomerulosclerosis | 5 (15.1) |
| Mesangio proliferative glomerulonephritis | 5 (15.1) |
| Antral gastritis | 15 (45.5) |
| Erosive gastritis | 2 (6) |
| Pangastritis | 13 (39.4) |
| Bulbilis | 3 (9.1) |

Statistical analysis

All analyses were performed using the SPSS 15.0 package (SPSS Inc., Chicago, IL) for Windows. While data with normal distribution were given as mean ± standard deviation, data without normal distrib-
were given as median (minimum-maximum).
In data analysis, the Wilcoxon test for the comparison of medians in dependent groups, Student t-test for the comparison of averages, and non-
parametric tests were used. For all statistical tests, a p value under 0.05 was considered significant.

Nephrotic range proteinuria was described as 3.5 g/day creatinine or higher proteinuria. Renal failure was defined as serum creatinine above 1.3 mg/dl, hypoalbuminemia was defined as 35 g/l below the value of serum albumin. Patients who were shown to have malignancies, diabetes mellitus, liver disease, stage 3–4 cardiac failure, or acute coronary syndrome, pregnancy or active infection within the last 2 months were excluded. Likewise, patients with renal lesion and/or hypertension at the time of diagnosis, those with a history of acid-suppressive drug use within the last 6 months, those with a history of upper gastrointestinal sys-
tem disease or surgery, and those who previously received eradication therapy due to HP were not included in the study. None of the patients had been previously treated with immunosuppressive agents. The study protocol was approved by the local ethics committee.
The effect of Helicobacter pylori eradication on proteinuria in patients with primary glomerulonephritis

Table II. Findings before and after Helicobacter pylori eradication treatment

| Variable                          | Before treatment | After treatment | Value of p |
|-----------------------------------|------------------|-----------------|------------|
| Serum creatinine [mg/dl]          | 0.9 (0.5–1.2)    | 1.02 (0.6–1.29) | 0.021      |
| Serum total protein [g/l]         | 58.6 ±12.9       | 62.3 ±11.1      | 0.001      |
| Serum albumin [g/l]               | 34.0 (19.0–51.0) | 40 (20–52)      | 0.001      |
| Proteinuria [g/day]               | 3069 (652–12392) | 2850 (172–15181) | 0.990      |
| Serum total cholesterol [mg/dl]   | 246.6 ±89.2      | 227 ±64.3       | 0.460      |
| Serum triglyceride [mg/dl]        | 156 (55–464)     | 154 (51–356)    | 0.640      |
| Serum LDL [mg/dl]                 | 148 (65–404)     | 143 (78–268)    | 0.124      |
| Serum HDL [mg/dl]                 | 45.9 ±10.1       | 50.6 ±14.0      | 0.190      |
| hsCRP [mg/l]                      | 2.94 (0.4–4.6)   | 3.14 (0.7–4.2)  | 0.560      |

*Continuous variables are reported as mean (standard deviation) for normally distributed data or median (interquartile range) for asymmetrically distributed data.

Table III. Findings of glomerulonephritis subtypes before and after Helicobacter pylori eradication treatment

| Subtype of GN | Proteinuria [g/day] | Serum albumin [g/l] | Serum total protein [g/l] | Serum creatinine [mg/dl] |
|---------------|---------------------|---------------------|---------------------------|--------------------------|
|               | BT                  | AT                  | BT                        | AT                       |
| IgAN          | 5048 (652–12392)    | 3040 (172–8094)     | 39.2 (25–51)              | 41.3 (24–52)             |
|               |                     |                     | 64.9 (53–80)              | 67.3 (54–81)             |
|               |                     |                     |                           | 1.04 (0.72–1.20)         | 1.07 (0.70–1.29)         |
| MGN           | 6156 (2500–8588)    | 7027 (1560–15181)   | 28.7 (25–34)              | 33.1 (25–41)             |
|               |                     |                     | 47.4 (36–65)              | 55.6 (48–66)             |
|               |                     |                     |                           | 0.87 (0.54–1.27)         | 0.90 (0.65–1.20)         |
| MzPGN         | 2254 (814–4365)     | 2187 (654–4500)     | 39.5 (26–50)              | 41.7 (27–52)             |
|               |                     |                     | 64.7 (48–77)              | 66.1 (50–80)             |
|               |                     |                     |                           | 0.74* (0.50–0.92)        | 0.84** (0.60–1.03)       |
| MPGN          | 3726 (1532–6300)    | 3273 (1350–5460)    | 40.0 (31–47)              | 42.4 (30–49)             |
|               |                     |                     | 62.2 (47–73)              | 63.6 (51–74)             |
|               |                     |                     |                           | 0.93 (0.70–1.07)         | 0.96 (0.70–1.20)         |
| FSGS          | 4020 (1050–10800)   | 5037 (2152–9586)    | 40.0 (27–46)              | 40.5 (26–47)             |
|               |                     |                     | 60.3 (43–68)              | 62.3 (48–73)             |
|               |                     |                     |                           | 1.10 (0.90–1.20)         | 1.17 (1.08–1.20)         |

AT – after treatment, BT – before treatment, FSGS – focal segmental glomerulosclerosis, GN – glomerulonephritis, IgAN – IgA nephropathy, MGN – membranous glomerulonephritis, MPGN – membranoproliferative glomerulonephritis, MzPGN – mesangioproliferative glomerulonephritis

*When the values of each group after Helicobacter pylori treatment were compared, statistically significant differences were not found in any parameter other than the creatinine values of MzPGN patients (p = 0.027). **Continuous variables are reported as median (interquartile range) for data.

Table IV. Characteristics of patients who displayed significant regression in proteinuria after Helicobacter pylori eradication treatment

| Patient number | Age [years] | Gender | Subtype of GN | Hb [g/dl] | Creatinine [mg/dl] (BT) | Creatinine [mg/dl] (AT) | Albumin [g/l] (BT) | Albumin [g/l] (AT) | Proteinuria [g/day] (BT) | Proteinuria [g/day] (AT) |
|----------------|-------------|--------|--------------|-----------|-------------------------|-------------------------|-------------------|-------------------|--------------------------|--------------------------|
| 1              | 38          | F      | IgAN         | 12.4      | 1.20                    | 1.10                    | 26                | 24                | 11700                    | 1287                     |
| 2              | 35          | F      | IgAN         | 12.1      | 0.77                    | 0.97                    | 25                | 28                | 12392                    | 6160                     |
| 3              | 41          | M      | IgAN         | 15.0      | 1.20                    | 1.20                    | 49                | 51                | 2400                     | 172                      |
| 4              | 40          | M      | MGN          | 16.0      | 1.20                    | 1.20                    | 30                | 41                | 8588                     | 1560                     |
| 5              | 36          | M      | MPGN         | 13.1      | 1.07                    | 1.10                    | 45                | 49                | 2927                     | 1350                     |

AT – after treatment, BT – before treatment, F – female, GN – glomerulonephritis, Hb – hemoglobin, IgAN – IgA nephropathy, M – male, MGN – membranous glomerulonephritis, MPGN – membranoproliferative glomerulonephritis.
Discussion

We are of the opinion that HP eradication therapy significantly increases serum albumin levels in primary glomerulonephritis patients with dyspeptic complaints and HP positive upper gastrointestinal system pathology. The increase in serum albumin values may be attributed to the overall improvement ensured with the treatment of HP, an antigen which triggers the development of glomerulonephritis, or the improvement of appetite after HP eradication therapy caused by the elimination of dyspeptic complaints in patients with glomerulonephritis.

There are limited data supporting that HP eradication has a positive effect on proteinuria and that HP may be responsible for the pathogenesis of glomerulonephritis [15–18]. Kusano et al. studied HP prevalence in the palatine tonsils of patients with recurrent pharyngotonsilitis and IgAN, and concluded that HP may play a role in the antigenic stimulation which may cause IgA nephropathy [16]. In a similar study conducted with IgAN patients, mucosal inflammation dependent on HP was shown to have the potential to stimulate systemic antibody response [17]. Nagashima et al. examined the existence of HP with immunohistochemical labeling in the renal biopsy materials of 16 patients with MGN. They found that 7 of the MGN patients had granular deposits along the glomerular capillary walls and these reacted positively with HP specific antibody. The results suggested that HP infection may be involved in the pathogenesis of MGN [18]. In this study, we obtained an increase in serum albumin values and a decrease in proteinuria with HP eradication treatment. In spite of a statistically significant increase in the values of serum albumin, the decrease in proteinuria was not significant. At the same time, creatinine levels were significantly increased after the treatment. This may result from the improvement of activity in daily life after the treatment or the effects of ramipril used as an anti-proteinuric agent. The increase in serum albumin may have been associated with HP eradication or the improvement of dyspeptic complaints and thus increased appetite after HP eradication therapy. Five (15.1%) of the 33 patients displayed a notable regression in proteinuria in early stages after the treatment (Table IV). Of these patients, only one had been diagnosed with MGN. Thus, we are of the opinion that it is hard to attribute the positive development after eradication in these patients to spontaneous remission. The ramipril, aspirin, low protein diet and lipid reducing treatment through the study may also have contributed to the significant drop in proteinuria. However, all patients received this therapy. The presence of patients with remission, the decrease in proteinuria, and the significant increase in serum albumin and total protein levels seem to be promising.

In case reports and the few studies conducted, there is evidence for the positive course between HP eradication and the remission of glomerulonephritis [15, 19]. Sugimoto et al. obtained remission in an MGN patient who had not been previously treated by immunosuppressive therapy by using HP eradication. They stated that this result may have been induced by the low stage of MGN and the swift onset of HP eradication therapy [15]. Moriyama et al. studied HP prevalence and the effectiveness of eradication therapy on proteinuria in 32 MGN patients who were being treated with steroid therapy and had previously received immunosuppressive therapy, and found a higher HP prevalence among patients with MGN and obtained full remission in 3 MGN patients [19]. Membranous glomerulonephritis diagnosis was long term in all patients included in this study, and they received different immunosuppressive therapy before and during the study. Taking into consideration the population of this study and the fact that all patients received immunosuppressive therapy, we believe that it would be faulty to reach conclusions about the relationship between HP eradication and remission by using its results. Among our patients, immunosuppressive therapy started after HP eradication. Even though we had patients' long-term follow-up (12–18 months), we are of the opinion that it is not appropriate to discuss the results pertaining to this period as the immunosuppressive therapies received during this period may have been influential in the onset of remission. At the same time, immunosuppressive therapy was not delayed in any patient as it would not be ethical or legal. Long-term follow-up might be linked with spontaneous remission as well. We believe that associating the significant increase in serum albumin and total protein and the decrease in proteinuria with HP eradication may be possible with the help of comparisons of HP existence in liver tissue before and after the therapy via tissue level biopsies.

During the course of glomerulonephritis due to heavy proteinuria and loss of gamma globulins, infectious disease frequency may increase [20]. But in our study group of glomerulonephritis, we determined similar results of HP frequency with a population with dyspeptic complaints, as 76.7% and 67.6–81.3% [6], respectively. These results show us that there is no increase in HP frequency in patients with glomerulonephritis. In the theory of extragastrointestinal effect of HP, different local and systemic inflammatory processes have been blamed [4, 7, 11]. In the course of glomerulonephritis HP may have a role in the etiopathogenesis of diseases despite the low HP frequency. In our study although we demonstrated significant increase in serum albumin values, we could not controvert urine pro-
teinuria decrease significantly after HP eradication treatment. Our HP prevalence was similar to the normal population too. But we know that there would be different etiologic factors that can overlap in the diseases’ processes and etiopathogenesis that we could not ignore.

The major limitations of our study are the limited number of patients, limited time for follow-up after HP eradication, the failure of our design to provide clear information on long-term results, the impossibility of delaying immunosuppressive therapy in the long term due to ethical issues, and inability to show HP specific antibody existence in kidney tissue.

Our study is the first to investigate the effect of HP eradication treatment on the remission of the disease, in patients with primary glomerulonephritis and dyspeptic complaints. We suggest that HP eradication treatment has minor therapeutic effects on proteinuria and the remission of disease in patients with primary glomerulonephritis. Albumin levels can increase as a result of HP eradication therapy, and remission can be obtained in some patients. While these findings seem to suggest a relation between HP and the pathogenesis of glomerulonephritis, the lack of an accompanying decrease in proteinuria is a limitation parameter. The lack of a decrease in proteinuria does not mean that HP therapy is not effective in remission. We are of the opinion that attributing the pathogenesis of the disease to HP existence will be possible through future studies that show the existence of HP specific antibody in kidney biopsy material through immunohistochemical labeling and that reinvestigate the existence of HP through post-eradication control biopsies. However, it is obvious that this may involve ethical issues. Studies with a larger patient group may yield more specific results.

Conflict of interest

The authors declare no conflict of interest.

References

1. Cattran DC. Outcomes research in glomerulonephritis. Semin Nephrol 2003; 23: 340-54.  
2. Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant 1998; 13 (suppl. 1): 10-5.  
3. Jennette JC, Falk RJ. Glomerular clinicopathologic syndromes. In: Primer on kidney disease. Greenberg A, Cheung AK, Falk RJ, Coffman TM, Jennette JC (eds.). Elsevier Saunders, Philadelphia 2005; 150-98.  
4. Franceschi F, Gasbarrini A. Helicobacter pylori and extra-gastric diseases. Best Pract Res Clin Gastroenterol 2007; 21: 325-34.  
5. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52.  
6. Us D, Hascelik G. Seroprevalence of Helicobacter pylori infection in an asymptomatic Turkish population. J Infect 1998; 37: 148-50.  
7. Konturek SJ, Konturek PC, Pieniazek P, Bielański W. Role of Helicobacter pylori infection in extragastroduodenal disorders: introductory remarks. J Physiol Pharmacol 1999; 50: 683-94.  
8. Kanbay M, Kanbay A, Boyacıoglu S. Helicobacter pylori infection as a possible risk factor for respiratory system disease: a review of the literature. Respir Med 2007; 101: 203-9.  
9. Russo F, Jirillo E, Clemente C, et al. Circulating cytokines and gastrin levels in asymptomatic subjects infected by Helicobacter pylori (H. pylori). Immunopharmacol Immunotoxicol 2001; 23: 13-24.  
10. Bohr UR, Annibale B, Franceschi F, Roccarina D, Gasbar- 
rini A. Extragastric manifestations of Helicobacter pylori infection; other Helicobacters. Helicobacter 2007; 12 (suppl. 1): 45-53.  
11. Bodger K, Crabtree JE. Helicobacter pylori and gastric inflammation. Br Med Bull 1998; 54: 139-50.  
12. Budzynski J. The favourable effect of helicobacter pylori eradication therapy in patients with recurrent angina-like chest pain and non-responsive to proton pump inhibitors – a preliminary study. Arch Med Sci 2011; 7: 73-80.  
13. Beckman Coulter Synchron® Clinical Systems. Chemistry information manual. This manual is intended for use with Unicel® DxC 800. Beckman Coulter, Galway, Ireland. 2004; 12: 1-1193.  
14. Hegedus O, Ryden J, Rehnberg AS, Nilsson S, Hellstrom PM. Validated accuracy of a novel urea breath test for rapid Helicobacter pylori detection and in-office analysis. Eur J Gastroenterol Hepatol 2002; 14: 513-20.  
15. Sugimoto T, Furukawa T, Maeda T, Somura M, Uzu T, Ka-shiwagi A. Marked reduction of proteinuria after eradication of gastric Helicobacter pylori infection in a patient with membranous nephropathy: coincidental or associated? Intern Med 2007; 46: 1483-4.  
16. Kusano K, Tokunaga O, Ando T, Inokuchi A. Helicobacter pylori in the palatine tonsils of patients with IgA nephropathy compared with those of patients with recurrent pharyngotonsillitis. Hum Pathol 2007; 38: 1788-97.  
17. Barratt J, Bailey EM, Buck KS, et al. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 1999; 33: 1049-57.  
18. Nagashima R, Maeda K, Yuda F, Kudo K, Saitoh M, Ta-kahashi T. Helicobacter pylori antigen in the glomeruli of patients with membranous nephropathy. Virchows Arch 1997; 431: 235-9.  
19. Moriyama T, Kaneko T, Fujii M, Tsukakihara Y, Kawano S, Imai E. High prevalence of Helicobacter pylori infection in Japanese patients with membranous nephropathy. Aliment Pharmacol Ther 2006; 24 (suppl. 4): 189-93.  
20. Floege J, Feehally J. Introduction to glomerular disease: clinical presentations. In: Comprehensive clinical nephrology. Feehally J, Floege J, Johnson RJ (eds.). Mosby, Philadelphia 2007; 193-208.